Media OutReach
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251. United Biotechnology will retain the rights for UBT251 in Chinese mainland, Hong Kong, Macau, and Taiwan. United Biotechnology is eligible to receive an upfront payment of 200 million US dollars and potential milestone payments of up to 1.8 billion dollars from Novo Nordisk, as well as tiered royalties on net sales outside of Chinese mainland, Hong Kong, Macau, and Taiwan.
“Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “We look forward to building on United Biotechnology’s scientific work and further exploring the potential best-in-class properties of UBT251 across cardiometabolic disease indications.”
United Biotechnology recently completed a randomized, double-blind, placebo-controlled phase 1b trial in China designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple subcutaneous injections of UBT251 in people with overweight or obesity.
A total of 36 patients were enrolled in three different dose groups (1mg, 1mg/3mg, 1mg/3mg/6mg). Each group adopted a dose titration method, with subcutaneous injection once a week for 12 consecutive weeks.
The safety profile of UBT251 was consistent with incretin-based therapies. The most common adverse events were gastrointestinal and the vast majority were mild to moderate in severity. In the highest dose group, the average weight of the people who completed the trial decreased by 15.1% from baseline, while the average weight of people in the placebo group increased by 1.5% from baseline.
“We are pleased to announce our exclusive license agreement with Novo Nordisk for UBT251. As a leading global biopharmaceutical company, Novo Nordisk holds a strong position in the treatment of chronic diseases,” said Mr. Tsoi Hoi Shan, the Chairman of TUL. “TUL is committed to strengthening its presence in the treatment of chronic diseases, including endocrine and metabolic disorders, while actively expanding its footprint in global markets. We believe that Novo Nordisk’s expertise will play a key role in accelerating the global development of UBT251.”
This collaboration represents a pivotal milestone in TUL’s ongoing efforts to establish a global strategic presence and demonstrates its commitment to innovation-driven transformation. TUL will continue to foster scientific innovation, advance high-quality and sustainable development, and accelerate the establishment of a globally competitive framework for manufacturing, R&D, and commercialization.
The closing of this transaction is subject to applicable regulatory clearance and other customary closing conditions.
Hashtag: #TUL
The issuer is solely responsible for the content of this announcement.
About UBT251
UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has demonstrated potent activity on all three receptors in a preclinical setting.
UBT251 is categorized as a Class 1 innovative drug in China, being developed by United Biotechnology for multiple indications. To date, UBT251 has been approved for clinical trials in China in adult type 2 diabetes, overweight or obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), and chronic kidney disease (CKD), and for clinical trials in the United States in adult type 2 diabetes, overweight or obesity, and CKD.
United Biotechnology recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.
About TUL and United Biotechnology
Founded in 1990, TUL (HKEX: 3933) is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. TUL currently boasts seven production bases, covering intermediate products, bulk medicine , finished products, veterinary drugs, empty capsule casings, and medical devices, with the sales networks dotted across nearly 80 countries and regions. United Biotechnology, located in the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, serves as the biopharmaceutical R&D headquarter of TUL. United Biotechnology focuses on the development of high-end biopharmaceuticals to treat major chronic diseases. For more information, please visit www.tul.com.cn.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, 
Facebook, 
X, 
LinkedIn and 
YouTube.
GoTyme Bank becomes the first digital bank in the Philippines to enable Apple Pay, expanding secure and seamless digital payments for 10 million customers
MANILA, PHILIPPINES – Media OutReach Newswire – 18 August 2026 – Paymentology, the leading global issuer processor, today announced the successful launch of Apple Pay for GoTyme Bank in the Philippines. Through this launch, GoTyme becomes one of the first issuers in the Philippine market to enable Apple Pay, giving 10 million customers an easy, secure and private way to pay using their Apple devices.
As one of the country’s fastest-growing digital banks, GoTyme continues to accelerate its digital payments strategy by expanding secure, seamless and convenient payment experiences for Filipino consumers. Customers can now securely add their GoTyme debit card to Apple Wallet and make contactless payments in stores, within apps and online wherever Apple Pay is accepted.
Apple Pay uses industry-leading tokenisation technology, meaning card numbers are never stored on devices or shared with merchants. Instead, a unique Device Account Number is assigned, with every transaction authenticated through Face ID, Touch ID or a device passcode, providing an additional layer of security while delivering a fast, frictionless checkout experience.
Nate Clark, President and CEO at GoTyme Bank commented: “At GoTyme Bank, we’re constantly looking for ways to make banking simpler, safer and more rewarding for our customers. Bringing Apple Pay to GoTyme Bank customers in the Philippines gives them an easy and secure way to pay wherever they shop while continuing to earn rewards points on all their transactions. This is another step in our commitment to making everyday banking more beautiful and convenient for our customers.
The launch comes as digital payments continue to reshape the Philippine economy. According to the Bangko Sentral ng Pilipinas (BSP), digital payments now account for more than half of all retail payment transactions, as consumers increasingly embrace mobile-first banking and contactless payments. Meanwhile, smartphone penetration continues to rise, supporting growing demand for digital wallets and tokenised payment experiences. As digital commerce accelerates, enabling secure mobile payments through services such as Apple Pay is becoming an increasingly important differentiator for financial institutions.
Minh-Ha Truong, Head of Growth, APAC at Paymentology, added: “As a long-standing partner to GoTyme, we’re proud to support another significant milestone in its growth journey. Bringing Apple Pay to market demonstrates how modern, cloud-native issuer processing enables digital banks to rapidly deliver innovative payment experiences while maintaining the highest standards of security, scalability and performance. Together, we’re helping shape the future of digital payments in the Philippines.”
The launch further strengthens GoTyme’s position as one of Southeast Asia’s leading digital banks and highlights the value of Paymentology’s cloud-native issuer processing platform in helping banks and fintechs rapidly introduce innovative payment capabilities that meet evolving customer expectations.
Hashtag: #Paymentology
https://www.paymentology.com/
https://www.linkedin.com/company/paymentology/
https://x.com/Paymentology
The issuer is solely responsible for the content of this announcement.
Media OutReach
New Documentary Under the Hakka Liugdui Sun From Discovery to Debut on August 20 in Southeast Asia
Set against the sun-drenched landscapes of southern Taiwan, Under the Hakka Liugdui Sun highlights how the people of Liugdui have thrived alongside the land for over 300 years. Following local scholars, farmers, and artisans, the documentary explores how this community adapts its deep-rooted traditions—from water stewardship to food heritage—in response to environmental and economic change, offering vital modern insights on sustainability, rural revitalization, and cultural continuity.
Across three episodes—Water, agriculture, and food—the documentary explores how the people of Liugdui blend tradition with modern innovation. Viewers meet groundwater experts, farmers pioneering sustainable crops, and artisans repurposing local materials like betel nut, alongside culinary practitioners who preserve Hakka identity through ancestral rituals, communal feasts, and family traditions that unite generations.
Audiences will discover a community that views tradition not as something fixed in the past, but as a living legacy that continues to evolve. From innovative groundwater management and botanical dyeing to ritual feasts and modern interpretations of Hakka cuisine – the documentary celebrates the creativity, resilience, and values that have sustained Liugdui for centuries.
Under the Hakka Liugdui Sun premieres in Southeast Asia on Discovery Channel, Thursday, August 20 at 7:10pm; TLC Channel, Monday, August 24 at 7:10pm; and Discovery Asia, Tuesday, August 25 at 9:25pm.
Hashtag: #Discovery
The issuer is solely responsible for the content of this announcement.
About Discovery Channel
The launch press conference broke away from tradition with a vibrant runway show featuring celebrity “Hot Spring Travel Navigators,” including acclaimed chef Edward Lee from Netflix’s Culinary Class Wars, visual identity creative director Yen Po-Chun, TSUTAYA BOOKSTORE Taiwan Chairman Kazuma Otsuka, and actor-host Andrew Chau. Together with local businesses, they showcased regional agriculture, specialties, and lifestyle products.
The official launch celebration kicks off on September 4 at Guguan Park in Taichung, featuring a themed parade with over 500 participants and the lighting ceremony for the Lishan–Guguan Light Art Festival, which stars a massive eight-meter “OhBear” light installation. The festivities continue on September 5 with a guided tribal trekking tour in Guguan, offering participants an exclusive NT$500 accommodation discount.
To promote four-season wellness tourism globally, the campaign partners with the East Asia Hot Spring Association for an international symposium on September 4. Key promotions also include complimentary LINE POINTS for new followers, curated packages starting at NT$299, and a flash sale of 800 limited NT$1 Hot Spring Vouchers for the Double 11 Shopping Festival. Furthermore, cross-sector collaborations offer half-price entry to national forest areas, limited-edition Taiwan Railway bento boxes, and Guanziling mud spring skincare products to enrich the travel experience.Hashtag: #TaiwanFourSeasonSprings
https://www.trimt-nsa.gov.tw/zh-tw/
The issuer is solely responsible for the content of this announcement.
